Loading..

Lexicon Pharmaceuticals, Inc. (LXRX) Report Analysis

Corporate Events

Neutral

Lexicon Pharmaceuticals, Inc. Presents at 2022 ...

2022-06-01 12:00:00

Lexicon Pharmaceuticals, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 10:00 AM. Venue: Marriott Marquis, New York...

Positive

Lexicon Pharmaceuticals, Inc. Resubmits New Dru...

2022-05-31 12:00:00

Lexicon Pharmaceuticals, Inc. announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) se...

Neutral

Lexicon Pharmaceuticals, Inc. Approves Amended ...

2022-05-25 12:28:00

Lexicon Pharmaceuticals, Inc. announced at the AGM held on May 20, 2022 that the company approved Ratification and approval of the Company's T...

Neutral

Lexicon Pharmaceuticals, Inc., Q1 2022 Earnings...

2022-04-29 12:02:00

Lexicon Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 05, 2022

Neutral

Lexicon Pharmaceuticals, Inc. to Report Q1, 202...

2022-04-29 12:02:00

Lexicon Pharmaceuticals, Inc. announced that they will report Q1, 2022 results Pre-Market on May 05, 2022

Neutral

Lexicon Pharmaceuticals, Inc. Proposes to Ratif...

2022-04-08 10:12:00

Lexicon Pharmaceuticals, Inc. proposed to ratify and approve the Third Amended and Restated Certificate of Incorporation increasing the number...

Neutral

Lexicon Pharmaceuticals, Inc. - Shareholder/Ana...

2022-04-08 10:12:00

AGM

Neutral

Lexicon Pharmaceuticals, Inc., Annual General M...

2022-04-08 10:12:00

Lexicon Pharmaceuticals, Inc., Annual General Meeting, May 20, 2022, at 08:00 Central Daylight. Agenda: To consider election of the three Clas...

Neutral

Lexicon Pharmaceuticals, Inc. Presents at Needh...

2022-04-07 12:00:00

Lexicon Pharmaceuticals, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-12-2022 08:45 AM. Speakers: Jeffrey L. Wade, President & CFO.

Positive

Lexicon Pharmaceuticals, Inc. Announces Results...

2022-04-02 16:15:00

Lexicon Pharmaceuticals, Inc. announced results of a new analysis of data from the SCORED Phase 3 clinical trial of sotagliflozin that was pre...

Neutral

Lexicon Pharmaceuticals, Inc. Presents at Ameri...

2022-03-22 18:30:00

Lexicon Pharmaceuticals, Inc. Presents at American College of Cardiology Annual Scientific Session & Expo, Apr-01-2022 . Venue: Washington, Di...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Neutral

Needham & Company, LLC, Needham 21st Annual Hea...

2022-02-11 23:04:00

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.

Neutral

American College of Cardiology, Inc., American ...

2022-01-26 12:00:00

American College of Cardiology, Inc., American College of Cardiology Annual Scientific Session & Expo, Apr 01, 2022 through Apr 04, 2022. Venu...

Positive

Lexicon Submits New Drug Application for Sotagl...

2021-12-30 21:05:00

Lexicon Pharmaceuticals, Inc. announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval...

Positive

Lexicon Pharmaceuticals, Inc.(NasdaqGS:LXRX) ad...

2021-12-20 00:00:00

Lexicon Pharmaceuticals, Inc. has been added to NASDAQ Biotechnology Index.

Neutral

Lexicon Pharmaceuticals, Inc. Presents at Piper...

2021-11-22 15:06:00

Lexicon Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, Un...

Neutral

Lexicon Pharmaceuticals, Inc. Presents at Piper...

2021-11-22 05:04:00

Lexicon Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 .

Neutral

Lexicon Pharmaceuticals, Inc. Presents at 12th ...

2021-11-17 10:12:00

Lexicon Pharmaceuticals, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 . Venue: London, United Kingdom.

Positive

Lexicon Pharmaceuticals, Inc. Sotagliflozin Dem...

2021-11-14 13:35:00

Lexicon Pharmaceuticals, Inc. announced that a new analysis evaluating the clinical benefit of Lexicon’s investigational drug, sotagliflozin, ...

Positive

Lexicon Pharmaceuticals, Inc. to Present New An...

2021-11-09 13:00:00

Lexicon Pharmaceuticals, Inc. announced that a new analysis of sotagliflozin results from the SOLOIST and SCORED Phase 3 outcomes studies will...

Neutral

Lexicon Pharmaceuticals, Inc. to Report Q3, 202...

2021-10-28 23:27:00

Lexicon Pharmaceuticals, Inc. announced that they will report Q3, 2021 results After-Market on Nov 03, 2021

Neutral

Lexicon Pharmaceuticals, Inc., Q3 2021 Earnings...

2021-10-28 23:27:00

Lexicon Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 03, 2021

Neutral

Piper Sandler Companies, Piper Sandler 33rd Ann...

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Neutral

Lexicon Pharmaceuticals, Inc. Presents at Oppen...

2021-09-20 09:43:00

Lexicon Pharmaceuticals, Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-21-2021 10:45 AM.

Positive

Lexicon Pharmaceuticals, Inc.(NasdaqGS:LXRX) ad...

2021-09-20 00:00:00

Lexicon Pharmaceuticals, Inc.(NasdaqGS:LXRX) added to S&P Global BMI Index

Negative

Lexicon Pharmaceuticals, Inc. Appoints Jeffrey ...

2021-09-09 20:10:00

Lexicon Pharmaceuticals, Inc. announced on September 3, 2021, in preparation for the potential commercial launch of sotagliflozin, if approved...

Neutral

Lexicon Pharmaceuticals, Inc. Presents at Citi’...

2021-09-01 19:46:00

Lexicon Pharmaceuticals, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021 . Venue: New York, United States.

Positive

Lexicon’s Sotagliflozin Demonstrates Additional...

2021-08-23 10:09:00

Lexicon Pharmaceuticals, Inc. presented additional analyses of sotagliflozin data from the SOLOIST and SCORED Phase 3 clinical trials at ESC C...

Neutral

Lexicon Pharmaceuticals, Inc. has filed a Shelf...

2021-08-06 00:00:00

Lexicon Pharmaceuticals, Inc. has filed a Shelf Registration in the amount of $200 million. Security Name: Common Stock Security Name: P...

Neutral

Lexicon Pharmaceuticals, Inc. has filed a Shelf...

2021-08-06 00:00:00

Lexicon Pharmaceuticals, Inc. has filed a Shelf Registration in the amount of $2.154 million. Security Name: Common Stock Securities Offer...

Negative

Craig Granowitz Joins Lexicon Pharmaceuticals, ...

2021-07-30 11:01:00

Lexicon Pharmaceuticals, Inc. announced that Craig Granowitz, M.D., Ph.D. will join the company as senior vice president and chief medical off...

Neutral

Lexicon Pharmaceuticals, Inc., Q2 2021 Earnings...

2021-07-28 21:40:00

Lexicon Pharmaceuticals, Inc., Q2 2021 Earnings Call, Jul 30, 2021

Neutral

Lexicon Pharmaceuticals, Inc. to Report Q2, 202...

2021-07-28 21:40:00

Lexicon Pharmaceuticals, Inc. announced that they will report Q2, 2021 results Pre-Market on Jul 30, 2021

Neutral

Oppenheimer & Co. Inc., Oppenheimer Fall Health...

2021-07-21 14:31:00

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021.

Neutral

Lexicon Pharmaceuticals, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 10:00 AM

2022-06-01 12:00:00

Lexicon Pharmaceuticals, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 10:00 AM. Venue: Marriott Marquis, New York City, New York, United States. Speakers: Lonnel Coats, CEO & Director.

Positive

Lexicon Pharmaceuticals, Inc. Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure

2022-05-31 12:00:00

Lexicon Pharmaceuticals, Inc. announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of sotagliflozin for the treatment of heart failure. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. The NDA submission is supported by the results from the Phase 3 SOLOIST-WHF clinical study in patients with type 2 diabetes who had recently been hospitalized for worsening heart failure and the Phase 3 SCORED clinical study in patients with type 2 diabetes, chronic kidney disease and risks for cardiovascular disease. SOLOIST-WHF was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 1,222 patients with type 2 diabetes who had recently been hospitalized for worsening heart failure. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo. SCORED was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 10,584 patients with type 2 diabetes, chronic kidney disease with eGFR of 25 to 60 ml per minute per 1.73 m2 of body-surface area, and risks for cardiovascular disease. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo. Key secondary endpoints included total number of events of deaths from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke. Both SOLOIST-WHF and SCORED achieved their respective primary endpoints, with overall tolerability similar to placebo across both trials. Results from both studies were presented at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine (NEJM) in two separate articles titled: “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” and “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease” which may be accessed at www.nejm.org. Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an investigational oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, type 1 and type 2 diabetes, and chronic kidney disease in fourteen Phase 3 clinical studies involving approximately 20,000 patients.

Neutral

Lexicon Pharmaceuticals, Inc. Approves Amended and Restated Certificate of Incorporation

2022-05-25 12:28:00

Lexicon Pharmaceuticals, Inc. announced at the AGM held on May 20, 2022 that the company approved Ratification and approval of the Company's Third Amended and Restated Certificate of Incorporation.

Neutral

Lexicon Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 05, 2022

2022-04-29 12:02:00

Lexicon Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 05, 2022

Neutral

Lexicon Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022

2022-04-29 12:02:00

Lexicon Pharmaceuticals, Inc. announced that they will report Q1, 2022 results Pre-Market on May 05, 2022

Neutral

Lexicon Pharmaceuticals, Inc. Proposes to Ratify and Approve the Third Amended and Restated Certificate of Incorporation

2022-04-08 10:12:00

Lexicon Pharmaceuticals, Inc. proposed to ratify and approve the Third Amended and Restated Certificate of Incorporation increasing the number of authorized shares of common stock from 225,000,000 to 300,000,000 in its annual meeting held on May 20, 2022.

Neutral

Lexicon Pharmaceuticals, Inc. - Shareholder/Analyst Call

2022-04-08 10:12:00

AGM

Neutral

Lexicon Pharmaceuticals, Inc., Annual General Meeting, May 20, 2022

2022-04-08 10:12:00

Lexicon Pharmaceuticals, Inc., Annual General Meeting, May 20, 2022, at 08:00 Central Daylight. Agenda: To consider election of the three Class I directors named in this proxy statement; to consider proposal to ratify and approve the Third Amended and Restated Certificate of Incorporation increasing the number of authorized shares of common stock from 225,000,000 to 300,000,000; to consider an advisory vote to approve the compensation paid to named executive officers; and to consider other matters.

Neutral

Lexicon Pharmaceuticals, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-12-2022 08:45 AM

2022-04-07 12:00:00

Lexicon Pharmaceuticals, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-12-2022 08:45 AM. Speakers: Jeffrey L. Wade, President & CFO.

Positive

Lexicon Pharmaceuticals, Inc. Announces Results of New Analysis of Data from the Scored Phase 3 Clinical Trial of Sotagliflozin

2022-04-02 16:15:00

Lexicon Pharmaceuticals, Inc. announced results of a new analysis of data from the SCORED Phase 3 clinical trial of sotagliflozin that was presented at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22). The SCORED clinical trial randomized 10,584 patients with type 2 diabetes and chronic kidney disease to sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, or placebo. Treatment with sotagliflozin resulted in a significant reduction in major adverse cardiovascular events (MACE) of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in the entire cohort as compared to placebo. This analysis also evaluated the effect of sotagliflozin on MACE in prespecified subgroups of patients with cardiovascular disease (CVD; n=5,144) and without CVD (n=5,440) at baseline. The analysis showed consistent reductions in MACE in both subgroups with a relative risk reduction in MACE of 21% in patients with and 26% in patients without CVD, in each case compared to placebo. SCORED was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 10,584 patients with type 2 diabetes, chronic kidney disease with eGFR of 25 to 60 ml per minute per 1.73 m2 of body-surface area, and risks for cardiovascular disease. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo. Key secondary endpoints included total number of events of deaths from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke. Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an investigational oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, type 1 and type 2 diabetes, and chronic kidney disease in fourteen Phase 3 clinical studies involving approximately 20,000 patients.

Neutral

Lexicon Pharmaceuticals, Inc. Presents at American College of Cardiology Annual Scientific Session & Expo, Apr-01-2022

2022-03-22 18:30:00

Lexicon Pharmaceuticals, Inc. Presents at American College of Cardiology Annual Scientific Session & Expo, Apr-01-2022 . Venue: Washington, District Of Columbia, United States.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022

2022-02-11 23:04:00

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.

Neutral

American College of Cardiology, Inc., American College of Cardiology Annual Scientific Session & Expo, Apr 01, 2022 through Apr 04, 2022

2022-01-26 12:00:00

American College of Cardiology, Inc., American College of Cardiology Annual Scientific Session & Expo, Apr 01, 2022 through Apr 04, 2022. Venue: Washington, District Of Columbia, United States.

Positive

Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults with Type 2 Diabetes

2021-12-30 21:05:00

Lexicon Pharmaceuticals, Inc. announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of sotagliflozin to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening heart failure or additional risk factors for heart failure irrespective of left ventricular ejection fraction. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. The NDA submission is supported by the results from the Phase 3 SOLOIST clinical study in patients with type 2 diabetes who had recently been hospitalized for worsening heart failure and the Phase 3 SCORED clinical study in patients with type 2 diabetes, chronic kidney disease and risks for cardiovascular disease. SOLOIST was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 1,222 patients with type 2 diabetes who had recently been hospitalized for worsening heart failure. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo. SCORED was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 10,584 patients with type 2 diabetes, chronic kidney disease with eGFR of 25 to 60 ml per minute per 1.73 m2 of body-surface area, and risks for cardiovascular disease. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo.

Positive

Lexicon Pharmaceuticals, Inc.(NasdaqGS:LXRX) added to NASDAQ Biotechnology Index

2021-12-20 00:00:00

Lexicon Pharmaceuticals, Inc. has been added to NASDAQ Biotechnology Index.

Neutral

Lexicon Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021

2021-11-22 15:06:00

Lexicon Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Neutral

Lexicon Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021

2021-11-22 05:04:00

Lexicon Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 .

Neutral

Lexicon Pharmaceuticals, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021

2021-11-17 10:12:00

Lexicon Pharmaceuticals, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 . Venue: London, United Kingdom.

Positive

Lexicon Pharmaceuticals, Inc. Sotagliflozin Demonstrates Benefits in Heart Failure and Blood Glucose Control Across the Full Range of Kidney Function in New Analysis of Clinical Data

2021-11-14 13:35:00

Lexicon Pharmaceuticals, Inc. announced that a new analysis evaluating the clinical benefit of Lexicon’s investigational drug, sotagliflozin, in heart failure and blood glucose control across the full range of kidney function was presented at the virtual American Heart Association Scientific Sessions 2021. Heart and kidney disease are often interconnected, with chronic kidney disease considered to be an independent risk factor for heart failure and cardiovascular disease. It is estimated that around half of patients with type 2 diabetes have chronic kidney disease. The pooled analysis of clinical data from the SOLOIST and SCORED trials involved a total of 11,806 patients with diabetes and heart failure or cardiovascular risk factors.

Positive

Lexicon Pharmaceuticals, Inc. to Present New Analysis At the American Heart Association Scientific Sessions 2021 Evaluating Cardiovascular Benefits Across Baseline Kidney Function

2021-11-09 13:00:00

Lexicon Pharmaceuticals, Inc. announced that a new analysis of sotagliflozin results from the SOLOIST and SCORED Phase 3 outcomes studies will be presented at the virtual American Heart Association Scientific Sessions 2021. The new analysis will be presented by Deepak L. Bhatt, M.D., M.P.H., executive director of Interventional Cardiovascular Programs at Brigham and Women's Hospital, professor of medicine at Harvard Medical School, and study chair for the SOLOIST and SCORED trials. The presentation is entitled, “Cardiovascular Benefits of Sodium Glucose Cotransporter-1/2 Inhibition with Sotagliflozin Across Baseline Kidney Function.” The presentation will be broadcast live at 8:24 a.m. Eastern on Sunday, November 14 during the main featured science session entitled, “Cardiometabolic Disease and Heart Failure: Digging Deeper and Treating Earlier” and the abstract will be posted on the AHA website at that time. SOLOIST was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 1,222 patients with type 2 diabetes who had recently been hospitalized for worsening heart failure. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo. SCORED was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 10,584 patients with type 2 diabetes, chronic kidney disease with eGFR of 25 to 60 ml per minute per 1.73 m2 of body-surface area, and risks for cardiovascular disease. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo. Both SOLOIST and SCORED achieved their respective primary endpoints. Results from both studies were presented at the Late-Breaking Science Session of the American Heart Association Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine in two separate articles titled: “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” and “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease".

Neutral

Lexicon Pharmaceuticals, Inc. to Report Q3, 2021 Results on Nov 03, 2021

2021-10-28 23:27:00

Lexicon Pharmaceuticals, Inc. announced that they will report Q3, 2021 results After-Market on Nov 03, 2021

Neutral

Lexicon Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 03, 2021

2021-10-28 23:27:00

Lexicon Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 03, 2021

Neutral

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Neutral

Lexicon Pharmaceuticals, Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-21-2021 10:45 AM

2021-09-20 09:43:00

Lexicon Pharmaceuticals, Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-21-2021 10:45 AM.

Positive

Lexicon Pharmaceuticals, Inc.(NasdaqGS:LXRX) added to S&P Global BMI Index

2021-09-20 00:00:00

Lexicon Pharmaceuticals, Inc.(NasdaqGS:LXRX) added to S&P Global BMI Index

Negative

Lexicon Pharmaceuticals, Inc. Appoints Jeffrey L. Wade as President, Effective October 1, 2021

2021-09-09 20:10:00

Lexicon Pharmaceuticals, Inc. announced on September 3, 2021, in preparation for the potential commercial launch of sotagliflozin, if approved, and management of future growth of the company, the board of directors appointed Jeffrey L. Wade as president, effective October 1, 2021, continuing to report to Lonnel Coats, who remains the company's chief executive officer. As of the effective date of Mr. Wade's appointment, Mr. Coats will continue to serve as the company's chief executive officer and perform the function of the company's principal executive officer and Mr. Wade will serve as president and chief financial officer and perform the functions of president and principal financial officer.

Neutral

Lexicon Pharmaceuticals, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021

2021-09-01 19:46:00

Lexicon Pharmaceuticals, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021 . Venue: New York, United States.

Positive

Lexicon’s Sotagliflozin Demonstrates Additional Compelling Benefits in Reducing Cardiovascular Endpoints: Results from Soloist and Scored Trials

2021-08-23 10:09:00

Lexicon Pharmaceuticals, Inc. presented additional analyses of sotagliflozin data from the SOLOIST and SCORED Phase 3 clinical trials at ESC Congress 2021 - The Digital Experience. Sotagliflozin is a first-in-class, investigational dual SGLT1 and SGLT2 inhibitor that showed substantial reductions, compared to placebo, in the primary endpoint of total cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure in both studies in patients with type 2 diabetes and worsening heart failure or chronic kidney disease. Dr. Bhatt presented these new findings in a virtual podium presentation entitled, “Benefits of SGLT2-1/2 Inhibition on Heart Failure, Ischemic, and Kidney Endpoints.” The new analyses evaluated the effect of titrating sotagliflozin from the initial daily dose of 200 mg to 400 mg on the primary endpoint (a composite endpoint of cardiovascular death, heart failure hospitalizations and urgent visits for heart failure) and other cardiorenal endpoints from the SOLOIST and SCORED trials. Approximately 73% of patients titrated to sotagliflozin 400 mg during the studies. Reductions in heart failure-related events were more pronounced at the target daily dose of sotagliflozin 400 mg, whereas similar results were observed between sotagliflozin 200 and 400 mg with other endpoints.

Neutral

Lexicon Pharmaceuticals, Inc. has filed a Shelf Registration in the amount of $200 million.

2021-08-06 00:00:00

Lexicon Pharmaceuticals, Inc. has filed a Shelf Registration in the amount of $200 million. Security Name: Common Stock Security Name: Preferred Stock Security Name: Debt Securities Security Name: Warrants Security Name: Rights Security Name: Units Transaction Features: Omnibus/Universal Shelf Registration

Neutral

Lexicon Pharmaceuticals, Inc. has filed a Shelf Registration in the amount of $2.154 million.

2021-08-06 00:00:00

Lexicon Pharmaceuticals, Inc. has filed a Shelf Registration in the amount of $2.154 million. Security Name: Common Stock Securities Offered: 600,000 Transaction Features: ESOP Related Offering

Negative

Craig Granowitz Joins Lexicon Pharmaceuticals, Inc as Senior Vice President and Chief Medical Officer, Effective August 2, 2021

2021-07-30 11:01:00

Lexicon Pharmaceuticals, Inc. announced that Craig Granowitz, M.D., Ph.D. will join the company as senior vice president and chief medical officer, effective August 2, 2021. Dr. Granowitz joins Lexicon with deep and successful leadership experience in the pharmaceutical industry, having previously built global medical organizations at three separate companies. Before joining Lexicon, Dr. Granowitz served as chief medical officer at Amarin Corporation plc, where he was a key leader on the company’s clinical development programs and held a number of other medical, safety and communications responsibilities.

Neutral

Lexicon Pharmaceuticals, Inc., Q2 2021 Earnings Call, Jul 30, 2021

2021-07-28 21:40:00

Lexicon Pharmaceuticals, Inc., Q2 2021 Earnings Call, Jul 30, 2021

Neutral

Lexicon Pharmaceuticals, Inc. to Report Q2, 2021 Results on Jul 30, 2021

2021-07-28 21:40:00

Lexicon Pharmaceuticals, Inc. announced that they will report Q2, 2021 results Pre-Market on Jul 30, 2021

Neutral

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021

2021-07-21 14:31:00

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021.

Fundamental Summary

Lexicon Pharmaceuticals's financial results from Q4 demonstrated decent performance, but will likely only help Lexicon Pharmaceuticals remain on par with its peers. Its growth and income factors appear positive and give support for optimism regarding the likelihood of continued positive performance. Overall, Lexicon Pharmaceuticals's growth and income factors are trending positively, and we, therefore, give Lexicon Pharmaceuticals an overall grade of 61 and a HOLD recommendation.

Lexicon Pharmaceuticals reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 23.48 million compared to USD 20.96 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 0.15 a year ago. Diluted loss per share from continuing operations was USD 0.16 compared to USD 0.15 a year ago.

Business Description

Lexicon Pharmaceuticals, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Sector Overview

Lexicon Pharmaceuticals is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Lexicon Pharmaceuticals's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 136.9 -20.6% 68
Liabilities 23.3 -34.7% 48
Price to Book 5.2 -1.4% 51
Cash & Equivalents 64.1 -30.5% 43
Equity 113.6 -16.8% 51
EBITDA -86.8 -26.8% 48
Total Revenues 0.3 -38.3% 98
Parameter Value Change Score
Return on Equity -65.0 -7.8% 82
Net Cashflow -62.2 -256.0% 91
Capital Expenditure -1.2 -112.5% 39
Asset Turnover 0.0 -36.4% 46
Free Cashflow -0.6 15.5% 82

* All values are TTM

The below chart reflects Lexicon Pharmaceuticals's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Lexicon Pharmaceuticals's peer average final assessment score stands on 64.0, Lexicon Pharmaceuticals's score is 61.

  •  LXRX
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 15 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 16 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 17 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 18 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 19 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 20 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 22 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 23 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 24 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 26 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 28 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 30 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 31 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 32 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 33 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 34 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 36 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 37 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 38 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 39 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 40 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 41 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 42 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 43 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 44 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Lexicon Pharmaceuticals's stock is now priced above its 5-day and 50-day, but below its 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in both the short and medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Lexicon Pharmaceuticals's stock indicates that it's likely oversold. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 68.

Neutral 68
Close Price 2.15
52W Low 1.31
52W High 6.16
5D MA 2.06
50D MA 1.79
200D MA 3.32
MACD 0.07
RSI 1.99
STOCH 95.45

Balance Sheet Analysis

Lexicon Pharmaceuticals's recently published balance sheet showed overall, underwhelming numbers. Both Cash & Equivalents and Liabilities were particularly concerning. Lexicon Pharmaceuticals did a poor job related to managing cash and cash equivalents this period, which stood at 64.1, representing a -30.5% change from the previous filing. The company's cash and cash equivalents metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Its cash and cash equivalents movement, therefore, received a grade of 43. Also, Lexicon Pharmaceuticals's liabilities stood at 23.3 in the current filing, which represents a -34.7% change from the previous report. This performance is relatively weak in comparison to their peers and suggests that its's stock price will likely suffer until this is solved. Discouraging results like these statistically lead to negative movement in stock prices, so we rated their liabilities movement component 48. That said, one metric, Assets, stood out as strongly positive. Lexicon Pharmaceuticals assets on their balance sheet, moved to 136.9, which is a -20.6% change from the last period. This growth should support upward pressure on its's stock price, which better captures their intrinsic value. The company's asset component, therefore, received a grade of 68. Therefore, the company's balance sheet earned a grade of 51.

Parameter Value Change Score
Assets 136.9 -20.6% 68
Liabilities 23.3 -34.7% 48
Price to Book 5.2 -1.4% 51
Cash & Equivalents 64.1 -30.5% 43
Equity 113.6 -16.8% 51
* All values are TTM

The below chart describes Lexicon Pharmaceuticals's performance as reflected on its balance sheet with respect to its peers. While Lexicon Pharmaceuticals received a balance sheet score of 51, the average of its peers stands on 61.0.

  •  LXRX
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 15 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 16 1
Alkermes plc 5.0B 63 66 46 54 71 62 17 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 18 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 19 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 20 1
Natera, Inc. 3.6B 73 65 43 95 42 54 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 22 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 23 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 24 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 26 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 28 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 30 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 31 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 32 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 33 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 34 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 36 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 37 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 38 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 39 1
Geron Corporation 566.2M 69 72 37 59 62 60 40 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 41 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 42 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 43 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 44 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Overall, Lexicon Pharmaceuticals's critical income statement metrics appear to signal strong support and a high likelihood of positive growth going forward. Lexicon Pharmaceuticals reported highly encouraging numbers for its revenue efficiency. This characteristic can affect companies in the same industry and market capitalization by up to 12.9%. Their revenue efficiency, specifically in contrast to their industry peers', should support a positive movement in the company's stock price. As a result, its revenue efficiency earned a score of 98. Also, Return factors metrics and ratios were exceptional in this report. Lexicon Pharmaceuticals reported a return on equity (ROE) ratio of -65.0, representing a change of -7.8% from the last report. The company appears headed in the right direction in terms of these return factors, exhibiting prudent capital expenditure growth compared to its peers. Consequently, their return factors received a grade of 82. That said, one metric, EBITDA, stood out as strongly negative. Lexicon Pharmaceuticals reported concerning EBITDA this period. At filing, EBITDA was reported as -86.8, representing -26.8% change from the previous period. This metric might have a 23.8 percent impact on companies in the same industry and with the same market capitalization. Lexicon Pharmaceuticals appears to be headed in the wrong direction in terms of EBITDA momentum, likely due to insufficient capital controls and a weaker than expected overall financial performance. Therefore, their EBITDA component earned a score of 48. Its income statement, therefore, earned a score of 69.

Parameter Value Change Score
EBITDA -86.8 -26.8% 48
Total Revenues 0.3 -38.3% 98
Return on Equity -65.0 -7.8% 82
* All values are TTM

The below chart describes Lexicon Pharmaceuticals's performance as reflected on its income statement with respect to its peers. While Lexicon Pharmaceuticals received a income statement score of 69 , the average of its peers stands on 70.0.

  •  LXRX
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 15 1
Ascendis Pharma A/S 5.2B 38 68 46 54 16 1
Alkermes plc 5.0B 69 55 81 62 17 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 18 1
Novavax, Inc. 4.0B 41 89 54 75 19 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 20 1
Natera, Inc. 3.6B 52 51 78 52 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 22 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 23 1
Insmed Incorporated 2.4B 51 58 73 57 24 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 26 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 28 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 29 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 30 1
IVERIC bio, Inc. 1.1B 84 58 79 70 31 1
FibroGen, Inc. 1.0B 48 74 63 67 32 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 33 1
ImmunoGen, Inc. 946.1M 40 73 71 64 34 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 36 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 37 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 38 1
AnaptysBio, Inc. 586.3M 97 50 77 68 39 1
Geron Corporation 566.2M 89 67 73 78 40 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 41 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 42 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 43 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 44 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Lexicon Pharmaceuticals appears likely to maintain its strong cash flow metrics and momentum going forward. Lexicon Pharmaceuticals presents exciting net cash flow numbers for its recent financial release, illustrated by a net cash flow of -62.2, which is a change of -256.0% from the last filing. Their net cash flow metrics are especially remarkable relative to their peers. Hence, its net cash flow earned a score of 91. Also, Lexicon Pharmaceuticals did a great job related to free cash flow this period, which stood at -0.6, representing a 15.5% change from the previous filing. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.8%. The company's free cash flow metrics are especially strong compared to its peers. Management seems to balance cash flow management, asset growth, and resource allocations in general. Therefore, its free cash flow movement earned a score of 82. On the other hand, Capital Expenditure, jumped out as looking rather underwhelming. Lexicon Pharmaceuticals's published capital expenditures (CapEx) numbers were discouraging and reflected management's unbalanced growth strategy. Lexicon Pharmaceuticals recorded CapEx of -1.2, which represents a -112.5% change from the previous report. This performance is all the more uninspiring relative to their peers and competitors. Consequently, their CapEx movement received a grade of 39. Their cash flow received an overall score of 77.

Parameter Value Change Score
Net Cashflow -62.2 -256.0% 91
Capital Expenditure -1.2 -112.5% 39
Asset Turnover 0.0 -36.4% 46
Free Cashflow -0.6 15.5% 82
* All values are TTM

The below chart describes Lexicon Pharmaceuticals's performance as reflected on its cash flow with respect to its peers. While Lexicon Pharmaceuticals received a cash flow score of 77, the average of its peers stands on 70.0.

  •  LXRX
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 15 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 16 1
Alkermes plc 5.0B 89 95 76 80 92 17 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 18 1
Novavax, Inc. 4.0B 62 38 63 54 60 19 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 20 1
Natera, Inc. 3.6B 52 54 56 84 58 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 22 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 23 1
Insmed Incorporated 2.4B 79 80 61 89 82 24 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 26 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 28 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 29 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 30 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 31 1
FibroGen, Inc. 1.0B 86 74 48 87 84 32 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 33 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 34 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 36 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 37 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 38 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 39 1
Geron Corporation 566.2M 78 68 49 81 77 40 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 41 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 42 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 43 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 44 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.